Our technology overcomes the limitations of conventional cell therapy treatment
This approach offers two major advantages over traditional cell therapy administration:MSCs administered via injection or intravenous infusion have short half-lives. The duration of therapeutic activity is extended significantly by housing the MSCs in an extracorporeal device. Our technology overcomes MSC dosage limitations seen during injection or intravenous infusion.
Sentien has exclusively licensed IP that broadly covers the use of MSCs in extracorporeal devices for the treatment of acute organ failure and related indications.